格隆汇8月5日丨瑞联新材(688550.SH)在互动平台表示，公司医药业务目前主要以创新药中间体为主。 2025年上半年医药板块业务增长系客户采购需求调整和部分创新药中间体产品进一步放量所致。 ...

8月4日，沪深两融数据显示，瑞联新材上周累计获融资净买入额6694.94万元，居两市第133位，上周融 资买入额2.00亿元，偿还额1.33亿元。 瑞联新材所属概念板块包括：电子化学品、陕西板块、股权转让、沪股通、举牌、融资融券、预盈预 增、机构重仓、创新药、光刻机(胶)、OLED、西部大开发、新材料。 通过天眼查大数据分析，西安瑞联新材料股份有限公司共对外投资了11家企业，参与招投标项目5次， 知识产权方面有商标信息8条，专利信息188条，此外企业还拥有行政许可31个。 来源：金融界 资金流方面，瑞联新材近5日主力资金流入4374.83万元，区间涨幅5.43%；近10日主力资金流出4029.93 万元，区间跌幅2.69%。 天眼查商业履历信息显示，西安瑞联新材料股份有限公司，成立于1999年，位于西安市，是一家以从事 化学原料和化学制品制造业为主的企业。企业注册资本17210.7058万人民币，实缴资本5000.0003万人民 币。公司法定代表人为刘晓春。 ...

Group 1 - The core point of the article highlights the financing activities of RuiLian New Materials, indicating a net selling position in the recent trading days [1] - On August 1, RuiLian New Materials had a financing buy amount of 0.16 billion yuan, ranking 894th in the market, with a financing repayment amount of 0.17 billion yuan, resulting in a net sell of 1.459 million yuan [1] - Over the last three trading days, the financing buy amounts were 0.51 billion yuan, 0.22 billion yuan, and 0.16 billion yuan respectively [1] Group 2 - In terms of securities lending, on the same day, there were no shares sold or net sold, indicating no activity in this area [1]

Market Performance - The electronic chemicals sector declined by 1.53% on July 31, with Rongda Photoelectric leading the drop [1] - The Shanghai Composite Index closed at 3573.21, down 1.18%, while the Shenzhen Component Index closed at 11009.77, down 1.73% [1] Stock Performance - Siquan New Materials (301489) saw a significant increase of 20.00%, closing at 103.66 with a trading volume of 66,300 shares and a transaction value of 667 million [1] - Tiancheng Technology (688603) increased by 1.97%, closing at 65.26 with a trading volume of 98,000 shares and a transaction value of 659 million [1] - Other notable performances include Tongyu New Materials (301630) up by 0.91%, Guanghua Technology (002741) up by 0.61%, and Zhongshi Technology (300684) up by 0.50% [1] Capital Flow - The electronic chemicals sector experienced a net outflow of 795 million from institutional investors, while retail investors saw a net inflow of 851 million [3] - Speculative funds had a net outflow of 56.71 million [3]

Group 1 - RuiLian New Materials plans to terminate the raw material project of Weinan RuiLian Pharmaceutical due to uncertainties in the construction timeline of the second phase [1] - HaiDa Group reported a net profit of 2.639 billion yuan for the first half of 2025, a year-on-year increase of 24.16% [1] Group 2 - JinCheng Pharmaceutical's subsidiary received the CEP certificate for Oseltamivir phosphate chemical raw material from the European Medicines Agency [2] - WenFeng Co. announced that 124 million shares held by shareholder Zheng SuZhen will be judicially auctioned [3] Group 3 - ShanJin International plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [5] - XiDian Pharmaceutical's shareholders plan to reduce their holdings by up to 3% of the company's total shares [7] Group 4 - ZhongTung High-Tech's subsidiary intends to purchase assets from Wukuang Tungsten Industry for 135 million yuan [9] - ZhongTung High-Tech's subsidiary plans to implement a 1.4 billion micro-drill intelligent manufacturing project with an estimated total investment of 178 million yuan [10] Group 5 - TianYi Co. has been selected as the first candidate for two procurement projects by China Mobile, with a total share of 160% [11] - GuangKu Technology is planning a major asset restructuring and has suspended trading of its stock [13] Group 6 - FaShiLong's controlling shareholder plans to transfer part of its shares, with the stock resuming trading [14] - TaiGe Pharmaceutical's shareholder plans to reduce holdings by up to 3 million shares [15] Group 7 - DaLian ShengYa's controlling shareholder is set to change, with the stock resuming trading [16] - JuRan Smart Home announced the passing of its actual controller and CEO, Wang LinPeng [18] Group 8 - JingQuanHua's shareholder plans to reduce holdings by up to 1% of the company's total shares [19] - JiangTe Electric's control change has progressed, with the stock resuming trading [21] Group 9 - AiWei Electronics plans to issue convertible bonds to raise up to 1.901 billion yuan for various projects [22] - ShangWei New Materials stated that its stock price has significantly deviated from its current fundamentals [22] Group 10 - JingHe Integrated plans to invest 1.195 billion yuan in Anhui Jingmei to support its layout in the photomask industry [23]

证券代码：688550 证券简称：瑞联新材 公告编号：2025-068 西安瑞联新材料股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 西安瑞联新材料股份有限公司（下称"瑞联新材"或"公司"）第三届董事 会于2024年8月2日任期届满，公司已于2024年8月1日披露了《关于董事会及监事 会延期换届的提示性公告》（公告编号：2024-084）。根据《中华人民共和国公 司法》（下称《公司法》）、《上海证券交易所科创板股票上市规则》等法律、 法规以及《西安瑞联新材料股份有限公司章程》（下称《公司章程》）等相关规 定，公司开展董事会换届选举工作，现将本次董事会换届选举情况公告如下： 一、董事会换届选举的情况 公司于2025年7月28日召开第三届董事会2025年第二次临时会议，审议通过 了《关于董事会换届暨选举第四届董事会非独立董事的议案》和《关于董事会换 届暨选举第四届董事会独立董事的议案》。因公司拟修改章程取消监事会并增设 职工董事，第四届董事会将由5名非独立董事、3名独立董事和1名职工董事组成， 其中1名职工董事由 ...

Core Viewpoint - The company has decided to terminate the raw material drug project due to uncertainties in the project's second phase and aims to find more profitable projects for the remaining raised funds [2][8][10]. Fundraising Overview - The company raised a total of RMB 1,995.79 million by issuing 17.55 million shares at RMB 113.72 per share [2][3]. - As of June 30, 2025, the cumulative investment in the raw material drug project was RMB 178.70 million, with pending payments of RMB 6.11 million and remaining funds of RMB 215.69 million [2][6]. Investment Projects - The company has several fundraising investment projects, including: - OLED and other functional materials production project with a total investment of RMB 300.00 million [4]. - High-end liquid crystal display materials production project with a total investment of RMB 310.00 million [4]. - Resource harmless treatment project with a total investment of RMB 37.21 million [4]. - Research and testing center project with an investment of RMB 170.00 million [4]. - Working capital supplement of RMB 260.00 million [4]. Termination of Investment Project - The raw material drug project was intended to expand the company's pharmaceutical CDMO business, with a total investment of RMB 423.00 million, using RMB 369.00 million of excess raised funds [6][8]. - The first phase of the project has been completed, but the second phase has not started due to uncertainties in product planning and regulatory approval processes [7][8]. Impact of Termination - The decision to terminate the raw material drug project is based on current industry trends and aims to optimize the use of resources and funds, ensuring high-quality project implementation [8][10]. - The termination is not expected to adversely affect the company's normal operations and aligns with its long-term development strategy [8][10]. Review Procedures - The board and supervisory committee approved the termination of the investment project, which will be submitted for shareholder approval [10][11]. - The supervisory committee and the sponsor institution have expressed their agreement with the decision, confirming that it complies with relevant regulations and does not harm shareholder interests [10][11].

Core Viewpoint - Xi'an Ruilian New Materials Co., Ltd. has decided to abolish its supervisory board and amend its articles of association, transferring the supervisory functions to the audit committee of the board of directors [1][2]. Summary by Sections Cancellation of Supervisory Board and Amendment of Articles - The company will no longer have a supervisory board, with its powers being transferred to the audit committee of the board of directors [1]. - The decision was made in accordance with the revised Company Law of the People's Republic of China and related regulations [1]. - The company held a board meeting on July 28, 2025, to approve the proposal to amend the articles of association and abolish the supervisory board, pending approval from the shareholders' meeting [1]. Amendments to Articles of Association - The articles of association have been revised to remove references to the supervisory board and replace them with the audit committee [2]. - The amendments include changes to various clauses, such as the definition of the shareholders' meeting, which is now referred to as the "shareholders' assembly" [2]. - The company’s registered capital has been updated from RMB 172.107058 million to RMB 173.575305 million [5][6]. Responsibilities and Compliance - Until the shareholders' meeting approves the cancellation of the supervisory board, the existing supervisory board will continue to fulfill its supervisory duties in accordance with relevant laws and regulations [2]. - The company emphasizes the importance of maintaining compliance with the Company Law, Securities Law, and corporate governance standards during this transition [2].

Core Points - The internal control system of Xi'an Ruilian New Materials Co., Ltd. aims to strengthen the company's operations, ensure compliance with laws and regulations, and protect investors' rights [2][3] - The internal control system applies to the company and its subsidiaries, focusing on various operational aspects including sales, procurement, asset management, and information disclosure [3][6] Group 1: General Requirements - Internal control is defined as a process that provides reasonable assurance regarding the achievement of objectives related to compliance, operational efficiency, asset security, and accurate information disclosure [3][4] - The company is responsible for developing internal control systems tailored to its operational characteristics and environment, with the board of directors accountable for their effectiveness [3][4] Group 2: Key Control Activities - The internal control activities encompass all operational aspects, including sales, procurement, inventory management, and financial management, with a focus on related party transactions [6][8] - The company must establish management policies for internal and external information to ensure timely and accurate communication regarding operational and risk conditions [10][12] Group 3: Management of Subsidiaries - The company emphasizes strengthening control over its subsidiaries, including establishing control frameworks, coordinating operational strategies, and ensuring timely reporting of significant matters [11][12] - Subsidiaries are required to adhere to the internal control standards set by the company, ensuring a consistent approach to governance and risk management [12][13] Group 4: Related Party Transactions - The internal control system for related party transactions must adhere to principles of honesty, equality, and fairness, ensuring that such transactions do not harm the interests of the company or its shareholders [13][14] - The company must maintain an updated list of related parties and ensure that transactions are conducted transparently and with proper approval [14][15] Group 5: External Guarantees and Fund Usage - The company must conduct thorough assessments before providing external guarantees, ensuring that risks are managed and that counterparties are capable of fulfilling their obligations [18][19] - A robust management system for the use of raised funds is required, ensuring compliance with intended purposes and effective tracking of fund usage [30][31] Group 6: Information Disclosure - The company is required to establish an internal control system for information disclosure, ensuring that all significant information is reported accurately and timely [46][47] - The board secretary is designated as the primary contact for external information release, ensuring that unauthorized disclosures do not occur [48][49] Group 7: Internal Audit and Evaluation - An internal audit department is established to oversee the effectiveness of internal controls, reporting directly to the board and ensuring independence from financial departments [56][57] - The company must conduct annual evaluations of its internal control systems, disclosing findings and corrective actions taken to address any identified deficiencies [58][59]

Core Points - The document outlines the management system for the resignation of directors and senior management personnel at Xi'an Ruilian New Materials Co., Ltd, aiming to ensure corporate governance stability and protect shareholders' rights [1][2][3] Chapter Summaries Chapter 1: General Provisions - The system applies to all directors and senior management personnel regarding resignation, term expiration, dismissal, and other circumstances leading to actual departure [1] Chapter 2: Resignation Circumstances and Effectiveness - Directors can resign before their term ends by submitting a written resignation report, effective upon receipt by the board [3] - The company must complete the election of new directors within 60 days of a resignation to ensure compliance with legal and regulatory requirements [2] - Non-employee representative directors automatically resign if not re-elected by the shareholders' meeting, while employee representative directors resign upon the decision of the employee representative assembly [2] - The company can dismiss directors, with the dismissal effective on the date of the resolution [2] Chapter 3: Handover Procedures and Unfinished Matters - Departing directors and senior management must complete handover procedures within five working days after resignation, including transferring all relevant documents and materials [5] - If there are unfulfilled public commitments, departing personnel must provide a written explanation before leaving [5] Chapter 4: Responsibilities and Obligations of Departing Directors and Senior Management - Departing directors and senior management retain obligations of loyalty and confidentiality even after resignation [6] - They must report their shareholdings and any changes, with restrictions on share transfers for six months post-resignation [6] Chapter 5: Accountability Mechanism - Directors and senior management are liable for damages caused to the company due to violations of laws or regulations during their tenure, regardless of their resignation status [7] - The board will review any breaches of commitments or transfer issues and may pursue compensation for losses incurred [7] Chapter 6: Supplementary Provisions - The system will be effective upon approval by the board and will be interpreted by the board [7]